INTRODUCTION

Hepatitis C virus (HCV) is a major cause of chronic liver disease, including cirrhosis and liver cancer. The World Health Organization has reported that 170 million people are chronically infected with HCV globally [1]. The highest prevalence of HCV infection worldwide is in Egypt (15%) where 90% of HCV infection is genotype 4 [2].

Patients with chronic hepatitis C virus (ChHCV) infection have significantly increased prevalence of type 2 diabetes mellitus (T2DM), independent of liver disease stage compared with controls or hepatitis B virus (HBV)-infected patients. T2DM is a common comorbid condition in approximately one-third of individuals with ChHCV infection [3].

However, the mechanism by which the increased risk of diabetes occurs is not clear. HCV infection can trigger autoimmune reactions against pancreatic β-cells in genetically susceptible subjects leading to direct destruction of β-cells; thereby, causing type 1 diabetes [4]; or the mechanism may be related to increased insulin resistance (IR) [5].

Patients with ChHCV infection have significantly increased prevalence of T2DM, independent of liver disease stage compared with controls or HBV-infected patients. T2DM is a common comorbid condition in approximately one-thirds of HCV-infected individuals, possibly due to a direct or indirect effect of the virus on insulin sensitivity [5].

Studies show that HCV impairs glucose metabolism directly via viral proteins and indirectly by altering proinflammatory cytokine levels. The direct effect is due to HCV core protein that prevents the insulin receptor substrate-1 (IRS-1) association with its insulin receptor by increasing IRS-1 degradation through upregulation of serine/threonine phosphorylation or increased activity of suppressor of cytokine signaling 3 (SOCS3) [678]. These direct actions on the insulin-signaling pathway impair downstream signalling and appropriate regulation of glucose metabolism [9]. An indirect effect of HCV on insulin sensitivity has also been suggested to be due to increased production of proinflammatory cytokines (interleukin 6 and tumor necrosis factor α) from sinusoidal liver cells that interferes with insulin-signaling pathways and leads to IR [101112].

The realistic possibility of moving to interferon-free therapies offers avoidance of the autoimmune-mediated hyperglycemic effects of interferon. Moreover, these therapies offer an oral, well-tolerated treatment regimen of shorter duration, helping to attain a greater sustained virological response (SVR) after 12 weeks and may help to reduce the development of IR [13].

The aim of this work was to evaluate the factors associated with improved glycemic control by direct-acting antiviral agents (DAAs) in Egyptian T2DM patients with ChHCV genotype 4 infection.

METHODS

This study was conducted on 460 T2DM patients with ChHCV from among the outpatients of the Departments of Internal Medicine and Tropical Medicine of Menoufia University Hospital between February 2016 and December 2016. All patients had HCV genotype 4, which is the most common genotype in Egypt. The study protocol was approved by the Ethics Committee of the Menoufia University Faculty of Medicine, and the selected subjects gave prior consent to participate in the study.

All patients were subjected to detailed history taking including age, sex, body mass index (BMI), and duration and family history of T2DM. Four hundred patients received DAAs in the form of sofosbuvir+daclatasvir with or without ribavirin for 12 weeks, while the remaining 60 patients did not receive DAAs and served as a control group. Before starting DAA therapy, laboratory tests were carried out that included fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), qualitative HCV RNA polymerase chain reaction test, liver enzymes, serum bilirubin, serum albumin, and the international normalized ratio. FPG, HbA1c, and body weight were repeated after 3 months. The severity of liver disease was determined by using the Child-Pugh classification. Only class A and class B patients were included. During the study period, all patients were advised to maintain their usual diet regimen and physical activity. For better evaluation of the improvement in glycemic control, we used a composite end-point given by the reduction of FPG (of a minimum of 20 mg/dL) or HbA1c (of a minimum of 0.5%).

Patients with SVR after 3 months (378 patients, 94.5%) were divided into two groups according to the end-point of glycemic control; that is, the improved glycemic control (IGC) group, which comprised 292 patients (77.2%), and the non-improved glycemic control (NIGC) group, which included 86 patients (22.8%).

Statistical methodology

Data was analysed using SPSS version 15 (SPSS Inc., Chicago, IL, USA). Quantitative data were presented in mean±standard deviation. Qualitative data were presented in frequency and percentage. To compare between groups, we used Student t-test and chi-square test. Multivariate logistic regression was used to adjust the confounding factors. Significance level for P≤0.05.

RESULTS

SVR after 3 months was obtained in 378 patients (94.5%). According to the above-mentioned criteria of improvement in glycemic control, 292 patients (77.2%) achieved improvement in glycemic control after 3 months of DAA therapy compared with pretreatment levels (IGC group); the remaining 86 patients (22.8%) and the control group (60 patients) did not achieve improvement in glycemic control during the period of study (Table 1).

In the IGC group, 78 patients (26.7%) needed to decrease the dose of antidiabetic treatment; 61 patients needed to decrease the insulin dose and 17 patients needed to decrease the gliclazide dose. None of the IGC patients needed to decrease the dose of metformin or dipeptidyl peptidase-4 (DPP4) inhibitor.

After 3 months of DAA therapy, the mean value of reduction of FPG in the IGC group was 49.1 mg/dL with a maximum reduction of 88 mg/dL (from 240 to 152 mg/dL) observed in one patient; the mean reduction of HbA1c was 0.8% with a maximum reduction of 1.1% (from 8.7% to 7.6%) observed in one patient (Table 1).

There were no significant differences between the IGC and NIGC groups regarding age, sex, and BMI (before and after therapy). However, the percentage of patients with positive family history of T2DM, longer T2DM duration and Child-Pugh class B was significantly higher in the NIGC group (Table 2).

To adjust for confounding factors, multivariate logistic regression analysis was performed, and the results showed that the following factors had a significant influence on improved glycemic control: family history of T2DM, duration of T2DM, and severity of liver disease according to Child-Pugh classification (Table 3).

In the IGC group, no patients experienced hypoglycemia, but three patients experienced deterioration in diabetic retinopathy; all of them had a history of diabetic retinopathy before DAA therapy.

DISCUSSION

In the current study, 77.2% of SVR patients achieved improvement in glycemic control after 3 months of treatment. In the IGC group, 78 patients (26.7%) needed to decrease their dose of antidiabetic treatment.

The evidence for the effect of DAA therapy on T2DM is conflicting. One study suggested that the antiviral effects of danoprevir may decrease IR in patients with HCV genotype 1 [14]. Another study found that HCV suppression with DAA therapy produced a significant improvement in glycemic control regardless of genotype [15]. In contrast, a third study found that DAA therapy with sofosbuvir and ledipasvir led to the development of new-onset T2DM [16].

In the current study, the patients in the IGC group were on the following antidiabetic treatments: 251 patients on metformin, 56 on gliclazide, 101 on sitagliptin or linagliptin, and 153 on insulin. Some patients were on a combination therapy of two or three agents. In this group, 78 patients (26.7%) needed to decrease the dose of antidiabetic treatment (61 patients needed to decrease the insulin dose and 17 needed to decrease the gliclazide dose). Although the main side effect of sulfonylurea drugs such as gliclzide is hypoglycemia, none of IGC group experienced this because some patients on gliclazide had high HbA1c (>7%) at the start of antiviral treatment, so the decrease in plasma glucose did not lead to hypoglycemia. Moreover, gliclazide is metabolized in the liver, so improving the liver condition may lead to improvement in gliclazide metabolism and clearance. None of the IGC patients needed to decrease their metformin or DPP4 inhibitor doses, which may be expected as hypoglycemia rarely occurs with metformin and DPP4 inhibitors.

BMI was not an important factor in improving glycemic control with use of DAA treatment. One case with a significant improvement in diabetic control after successful HCV treatment with DAA therapy has been reported [17]. This improvement in insulin requirements and HbA1c persisted following viral clearance despite an increase in the patient's BMI.

The percentage of patients with positive family history of T2DM was significantly lower in the IGC group compared with the NIGC control group. In patients without family history of T2DM, the possibility of IR is likely due to HCV infection only, so the eradication of HCV infection helps to improve IR and glycemic control, unlike those with inherited IR. It might be useful to classify patients with hereditary IR or HCV-induced IR to define better the effect of HCV eradication on these distinct populations, but this is not always possible. Absence of family history of T2DM may help in this differentiation.

The duration of T2DM was significantly longer in the NIGC group compared with the IGC control group. Prolonged duration of T2DM may lead to more β-cell failure and so improvement in IR does not lead to marked improvement in glycemic control.

In the current study, 22.8% of SVR diabetic patients did not reach the end-point of glycemic improvement. This can be explained by three factors. First, the severity of liver disease may play an important role as the percentage of Child-Pugh class B patients was significantly higher in the NIGC group. The etiology of T2DM in HCV-infected individuals has been postulated to result from either hepatogenous T2DM resulting from advanced liver disease or classical T2DM due to virally mediated IR [18]. Second, HCV infection may affect glucose level by an autoimmune mechanism on β-cells and is not related to IR. Third, some of the patients in the NIGC group already had normal FPG and HbA1c.

Because all the patients in this study had HCV genotype 4, we cannot determine if the glycemic improvement with DAAs was genotype-related or not. Most genotypes of HCV increase IR and can induce T2DM. A significant correlation was found between genotype 1 or 4 infection and IR, both in the presence and absence of T2DM [19]. The association between HCV genotype and IR has also been investigated with one study revealing an SVR-induced reduction in IR in patients with HCV genotype 1 [20].

In the current study, the patients with normal baseline FPG and HbA1c did not experience hypoglycemia, which excluded the direct hypoglycemic effect of DAAs.

Although studying the microvascular complications of diabetes is outside the scope of this study, three patients showed deterioration in diabetic retinopathy in the IGC group. Although these patients had a history of diabetic retinopathy before DAA treatment, the question is why did the improvement of liver condition by DAAs lead to a deterioration of retinopathy? In an Egyptian study [21], retinopathy was higher in T2DM patients without HCV infection (36%) compared with ChHCV T2DM patients (18%). The low prevalence of diabetic retinopathy in patients with ChHCV may be related to liver disease-induced abnormalities protecting the cardio-vascular system from atherosclerosis (hypotension, coagulation defect, thrombocytopenia, and decreased lipoprotein(a)). Lipoprotein(a) competes with plasminogen for binding to fibrin and impairing fibrinolysis. High lipoprotein(a) is associated with the development and progression of diabetic retinopathy. These effects of ChHCV infection may decrease diabetes-induced hypercoagulation and premature atherosclerosis. Unlike nephropathy and neuropathy, diabetic retinopathy is not known to be one of the extrahepatic manifestations of HCV. The protective effect of HCV chronic liver disease on retinopathy makes the prevalence of retinopathy lower [21]. Therefore, improving the liver condition by virus eradication may lead to a deterioration of retinopathy in diabetic patients. However, detailed studies are required to clarify this.

In conclusion, diabetic patients receiving DAAs should be closely monitored for reduction of antidiabetic drugs especially insulin and insulin secretagogues to avoid hypoglycemic events. Improvement of glycemic control in HCV patients treated with DAAs is greater in patients without family history of T2DM, short duration of diabetes, and mild liver disease (Child-Pugh class A) but is not related to age, sex, and BMI. Prospective studies should be conducted to define better the effect of DAAs on IR of HCV suppression, to evaluate the long-term effects of DAAs on diabetes control, and to determine the sustained effects. In addition, studies are needed to detect the effect of improvement of liver condition after DAA therapy on the complications of T2DM, especially diabetic ret-inopathy.

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

REFERENCES

• 1. World Health Organization. Hepatitis C cited 2017 Jun 30. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
• 2. Amer FA, Gohar M, Yousef M. Epidemiology of hepatitis C virus infection in Egypt. Int J Trop Dis Health 2015;7:119-131.Article
• 3. Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 2012;18:1642-1651. ArticlePubMedPMC
• 4. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-229. ArticlePubMed
• 5. Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol 2011;17:4055-4062. ArticlePubMedPMC
• 6. Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes 2014;5:52-58. ArticlePubMedPMC
• 7. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-1508. ArticlePubMedPMC
• 8. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006;55:529-535. ArticlePubMedPMC
• 9. Parvaiz F, Manzoor S, Tariq H, Javed F, Fatima K, Qadri I. Hepatitis C virus infection: molecular pathways to insulin resistance. Virol J 2011;8:474ArticlePubMedPMCPDF
• 10. Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014;5:586-600. ArticlePubMedPMC
• 11. Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 2009;54:2699-2705. ArticlePubMedPDF
• 12. Pattullo V, Heathcote J. Hepatitis C and diabetes: one treatment for two diseases? Liver Int 2010;30:356-364. ArticlePubMed
• 13. Das G, Bolusani H. Hepatitis C virus infection and diabetes. Prac Diabetes 2016;33:123-128b.Article
• 14. Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y, Voitot H, Vidaud M, Seiwert S, Bradford B, Zeuzem S, Marcellin P. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010;59:1694-1698. ArticlePubMed
• 15. Pavone P, Tieghi T, d'Ettorre G, Lichtner M, Marocco R, Mezzaroma I, Passavanti G, Vittozzi P, Mastroianni CM, Vullo V. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect 2016;22:462.e1-462.e3.ArticlePubMed
• 16. Premji R, Roopnarinesingh N, Qazi N, Nylen ES. New-onset diabetes mellitus with exposure to ledipasvir and sofosbuvir. J Investig Med High Impact Case Rep 2015;3:2324709615623300.ArticlePubMedPMCPDF
• 17. Pashun RA, Shen NT, Jesudian A. Markedly improved glycemic control in poorly controlled type 2 diabetes following direct acting antiviral treatment of genotype 1 hepatitis C. Case Reports Hepatol 2016;2016:7807921ArticlePubMedPMCPDF
• 18. Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality? Dig Liver Dis 2016;48:105-111. ArticlePubMed
• 19. Chehadeh W, Abdella N, Ben-Nakhi A, Al-Arouj M, Al-Nakib W. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol 2009;24:42-48. ArticlePubMed
• 20. Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG. ACHIEVE-1 and ACHIEVE-2/3 Study Teams. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 2012;61:128-134. ArticlePubMed
• 21. El-Kafrawy N, El-Najjar M, Dawood A, Al-Belehy O. Relationship between chronic HCV infection and diabetic microvascular complications in Egyptian patients. Life Sci J 2011;8:344-350.

Table 1

Changes in FPG and HbA1c in IGC group before DAA, 3 months after therapy

Variable	IGC group (n=292)		NIGC group (n=86)		Control group (n=60)
	Before DAAs therapy	3 Months after therapy	Before DAAs therapy	3 Months after therapy	Baseline	After 3 months
FPG, mg/dL
Range	105–252	85–186	108–248	110–249	108–245	107–248
Mean±SD	184.5±27.9	136.5±22.5	179.9±25.6	181.2±25.9	178.1±24.3	180.1±26.2
HbA1c, %
Range	6.9–8.7	6.4–7.7	6.8–8.8	6.8–8.7	6.9–8.8	6.8–8.9
Mean±SD	8.1±0.44	7.3±0.34	8.2±0.48	8.1±0.46	8.2±0.43	8.3±0.46

FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; IGC, improved glycemic control; DAA, direct-acting antiviral agent; NIGC, non-improved glycemic control; SD, standard deviation.

Table 2

Comparison between IGC group and NIGC group as regards age, sex, BMI, duration of T2DM, family history of T2DM, and Child-Pugh classification

Variable	IGC group (n=292)	NIGC group (n=86)	P valuea
Age, yr	53.25±4.6	52.34±4.9	0.113b
BMI before therapy, kg/m2	27.76±2.7	27.24±2.98	0.130b
BMI after therapy, kg/m2	27.74±2.8	27.25±3.0	0.156b
Duration of T2DM, yr	9.41±4.69	13.24±4.25	0.001b
Sex			0.632c
Male	141 (48.3)	39 (45.3)
Female	151 (51.7)	47 (54.7)
Family history of T2DM			0.001c
Positive	125 (42.8)	58 (67.4)
Negative	167 (57.2)	28 (32.6)
Child-Pugh classification			0.021c
A	254 (87.0)	66 (76.7)
B	38 (13.0)	20 (23.3)

Values are presented as mean±standard deviation or number (%).

IGC, improved glycemic control; NIGC, non-improved glycemic control; BMI, body mass index; T2DM, type 2 diabetes mellitus.

^aProbability of statistical test is significant if ≤0.05, ^bt-test, ^cChi-square test.

Table 3

Multivariate logistic regression analysis for factors affected glycemic control with direct-acting antiviral agents

Factor	B	P value	Odds ratio	95% CI
Duration of T2DM (<7 years)	0.479	0.000	2.452	1.335–4.504
Child-Pugh classification (child A)	0.407	0.001	2.025	1.106–3.711
Family history of T2DM (negative)	0.916	0.000	2.767	1.667–4.595

CI, confidence interval; T2DM, type 2 diabetes mellitus.

Figure & Data

References

Citations

Citations to this article as recorded by  

• Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review
  Annalisa Cespiati, Inês Coelho Rodrigues, Inês Santos, Sara Policarpo, Sofia Carvalhana, Anna Ludovica Fracanzani, Helena Cortez‐Pinto
  Liver International.2024;[Epub]     CrossRef
• Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients
  Doaa Mohamed Abdelnajid, Ahmed Y. Elmowafy, Lionel Rostaing, Marwa T. Elrakaiby
  Medicine.2023; 102(28): e34125.     CrossRef
• Hypoglycemia associated with direct‐acting anti‐hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS)
  Yu Zhou, Wenhuo Xie, Chenhua Zheng, Libin Liu, Zhou Chen, Xiaolu Wang
  Clinical Endocrinology.2022; 96(5): 690.     CrossRef
• Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response
  Sara Cuesta-Sancho, Mercedes Márquez-Coello, Francisco Illanes-Álvarez, Denisse Márquez-Ruiz, Ana Arizcorreta, Fátima Galán-Sánchez, Natalia Montiel, Manuel Rodriguez-Iglesias, José-Antonio Girón-González
  World Journal of Hepatology.2022; 14(1): 62.     CrossRef
• Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?
  Giorgio Maria Saracco, Alfredo Marzano, Mario Rizzetto
  Biomedicines.2022; 10(3): 534.     CrossRef
• Hépatite B et C: une mise à jour sur lʼhépatite virale chronique
  Marie Ongaro, Francesco Negro
  Schweizer Gastroenterologie.2022; 3(1): 19.     CrossRef
• Effect of achieving sustained virological response with direct-acting antiviral agents on glycemic control in diabetic patients with chronic hepatitis C infection
  Mohamed El-Kassas, Runia El-Folly, Maram Aboromia, Heba Aly, Mohamed Bahgat, Mostafa Hamed
  Egyptian Liver Journal.2022;[Epub]     CrossRef
• Hepatitis C virus infection and diabetes: A complex bidirectional relationship
  Stefano Ciardullo, Alessandro Mantovani, Antonio Ciaccio, Marco Carbone, Pietro Invernizzi, Gianluca Perseghin
  Diabetes Research and Clinical Practice.2022; 187: 109870.     CrossRef
• Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?
  Rasha Youssef Hagag, Ahmed Fawzy Selim, Omneya Darrag, Hassan Zied, Mohamed Sabry Aboelnasr
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1261.     CrossRef
• Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals
  Nehal K. Abdel Fattah, Sara M. Shaheen, Osama A. Ahmed, Kadry Elsaeed, Nagwa A. Sabri
  F1000Research.2022; 11: 649.     CrossRef
• Hepatitis C virus, insulin resistance, and diabetes: A review
  Nabeel Alzahrani
  Microbiology and Immunology.2022; 66(10): 453.     CrossRef
• The Extent of Insulin Resistance in Patients That Cleared Viral Hepatitis C Infection and the Role of Pre-Existent Type 2 Diabetes Mellitus: A Meta-Analysis
  Marian-Sorin Popescu, Andrei Ioan Drocas, Andrei Osman, Dan-Mihai Firu, Vlad Pădureanu, Cristina Maria Mărginean, Daniel-Cristian Pîrvu, Radu Mitruț, Dragoș Nicolae Mărgăritescu, Antonia Radu, Daniela Calina, Anca Oana Docea, Paul Mitruț
  Reports.2022; 5(4): 42.     CrossRef
• Global longitudinal strain as a predictor of short-term effect of oral antiviral regimens on myocardium in Egyptian patients with chronic viral hepatitis C
  Hazem Mohammad-Ali Farrag, Mina Samir Monir, Wael Soliman Abdel-Dayem, Hisham Abdel-Haleem Ali, Alaa Mohammad Ibrahim
  The Egyptian Heart Journal.2021;[Epub]     CrossRef
• Residual risk of liver disease after hepatitis C virus eradication
  Francesco Negro
  Journal of Hepatology.2021; 74(4): 952.     CrossRef
• Extrahepatic Manifestations of Chronic HCV Infection
  Dan L. Longo, Patrice Cacoub, David Saadoun
  New England Journal of Medicine.2021; 384(11): 1038.     CrossRef
• Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents
  Sergio Estefan, Carlos Eduardo Brandão-Melo, Cintia Marques dos Santos Silva, Danilo Cosme Klein Gomes, Paula Cardoso, Marcia Helena S. Costa
  Frontiers in Medicine.2021;[Epub]     CrossRef
• Current situation of viral hepatitis in Egypt
  Ashraf Elbahrawy, Marwa K. Ibrahim, Ahmed Eliwa, Mohamed Alboraie, Ali Madian, Hussein Hassan Aly
  Microbiology and Immunology.2021; 65(9): 352.     CrossRef
• The impact of direct-acting antiviral treatment on glycemic homeostasis in patients with chronic hepatitis C
  Marco SACCO, Giorgio M. SARACCO
  Minerva Gastroenterology.2021;[Epub]     CrossRef
• The impact of HCV eradication on hyperglycemia, insulin resistance, cytokine production, and insulin receptor substrate-1 and 2 expression in patients with HCV infection
  Basant Mahmoud, Adel Abdel Moneim, Doaa Mabrouk
  Clinical and Experimental Medicine.2021; 22(4): 583.     CrossRef
• Systematic review: chronic viral hepatitis and metabolic derangement
  Chia‐Chi Wang, Pin‐Nan Cheng, Jia‐Horng Kao
  Alimentary Pharmacology & Therapeutics.2020; 51(2): 216.     CrossRef
• Effect of treatment with direct antiviral agents (DAAs) on glycemic control in patients with type 2 diabetes mellitus & hepatitis C virus genotype 4
  Hassan Yousef Zied, Nashwa Mohamed Abo Alnasr, Amal Said El-Bendary, Sherief Abd-Elsalam, Rasha Youssef Hagag
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(4): 679.     CrossRef
• Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus
  Pradeep Kumar Mada, Matthew E. Malus, Arvin Parvathaneni, Bing Chen, Gabriel Castano, Sharon Adley, Maureen Moore, Michinari Hieda, Mohammed J. Alam, Mark Feldman, John William King
  International Journal of Hepatology.2020; 2020: 1.     CrossRef
• Cirrhosis and insulin resistance: current knowledge, pathophysiological mechanisms, complications and potential treatments
  Frédéric Clarembeau, Georgia Bale, Nicolas Lanthier
  Clinical Science.2020; 134(16): 2117.     CrossRef
• Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control
  Jennifer Andres, Michael Barros, Michael Arutunian, Huaqing Zhao
  Journal of Managed Care & Specialty Pharmacy.2020; 26(6): 775.     CrossRef
• Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy
  Francesco Negro
  Cold Spring Harbor Perspectives in Medicine.2020; 10(4): a036921.     CrossRef
• The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm
  Davide Giuseppe Ribaldone, Marco Sacco, Giorgio Maria Saracco
  Journal of Clinical Medicine.2020; 9(2): 563.     CrossRef
• Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals
  Riccardo Nevola, Luca Rinaldi, Letizia Zeni, Ferdinando C Sasso, Pia C Pafundi, Barbara Guerrera, Aldo Marrone, Mauro Giordano, Luigi E Adinolfi
  JGH Open.2020; 4(4): 713.     CrossRef
• Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control
  Mohamed Mohei El Badry, Doaa Abdelhady Ali, Noha Hamdy Eltaweel, Marwa A. Abdel-Wahed
  Egyptian Liver Journal.2020;[Epub]     CrossRef
• Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis
  Kamolyut Lapumnuaypol, David Pisarcik, Prapaipan Putthapiban, Weera Sukhumthammarat, Karn Wijarnpreecha, Charat Thongprayoon, Patompong Ungprasert
  Indian Journal of Medical Research.2020; 152(6): 562.     CrossRef
• Fisiopatología de la hepatitis C y diabetes mellitus. Hacia la cura de dos epidemias en el siglo XXI
  Harold Ariel Muñoz Díaz, Adán José Lúquez Mindiola, Andrés José Gómez Aldana
  Revista Colombiana de Gastroenterología.2019; 34(3): 277.     CrossRef
• Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients
  Giacomo Gastaldi, Diana Gomes, Philippe Schneiter, Xavier Montet, Luc Tappy, Sophie Clément, Francesco Negro, Jee-Fu Huang
  PLOS ONE.2019; 14(6): e0217751.     CrossRef
• The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis
  Carla Carnovale, Marco Pozzi, Alice Dassano, Francesca D’Addio, Marta Gentili, Carlo Magni, Emilio Clementi, Sonia Radice, Paolo Fiorina
  Acta Diabetologica.2019; 56(3): 341.     CrossRef
• Sustained Improvement in Type 2 Diabetes Mellitus is Common After Treatment of Hepatitis C Virus With Direct-acting Antiviral Therapy
  Amir Gilad, Zachary P. Fricker, Adam Hsieh, Dylan D. Thomas, Toni Zahorian, David P. Nunes
  Journal of Clinical Gastroenterology.2019; 53(8): 616.     CrossRef
• Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure
  Teegan R. Lim, Jonathan M. Hazlehurst, Andrei I. Oprescu, Matthew J. Armstrong, Sewa F. Abdullah, Nigel P. Davies, Robert Flintham, Peter Balfe, David J. Mutimer, Jane A. McKeating, Jeremy W. Tomlinson
  Clinical Endocrinology.2019; 90(3): 440.     CrossRef
• Direct‐acting antivirals for HCV treatment in older patients: A systematic review and meta‐analysis
  Rosanna Villani, Matteo Monami, Francesca Di Cosimo, Gilda Fioravanti, Edoardo Mannucci, Gianluigi Vendemiale, Gaetano Serviddio
  Journal of Viral Hepatitis.2019; 26(11): 1249.     CrossRef
• Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
  Sylvia Drazilova, Jakub Gazda, Martin Janicko, Peter Jarcuska
  Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1.     CrossRef
• The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic disease
  Zobair Younossi, Georgios Papatheodoridis, Patrice Cacoub, Francesco Negro, Heiner Wedemeyer, Linda Henry, Angelos Hatzakis
  Journal of Viral Hepatitis.2018; 25(S3): 6.     CrossRef
• Poor glycemic control and abrupt onset of diabetes in HCV patients receiving direct-acting antiviral drugs: case series
  Braira Wahid, Muhammad Wasim, Komal Saleem, Muhammad Waqar, Khansa Wahid, Manzoor Hussain, Muhammad Idrees
  Future Virology.2018; 13(8): 525.     CrossRef
• Risk of diabetes in HIV‐infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohort
  A. Provoost, M. Dramé, L. Cotte, L. Cuzin, R. Garraffo, D. Rey, F. Raffi, I. Poizot‐Martin, P. Pugliese, F. Bani‐Sadr
  Alimentary Pharmacology & Therapeutics.2018; 48(3): 281.     CrossRef
• The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C
  Luigi Elio Adinolfi, Luca Rinaldi, Aldo Marrone, Mauro Giordano
  Expert Review of Anti-infective Therapy.2018; 16(8): 595.     CrossRef
• Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
  Sylvia Drazilova, Martin Janicko, Lubomir Skladany, Pavol Kristian, Marian Oltman, Maria Szantova, Dusan Krkoska, Eva Mazuchova, Lubica Piesecka, Veronika Vahalova, Marek Rac, Ivan Schreter, Ladislav Virag, Tomas Koller, Adriana Liptakova, Miriam Ondrasov
  Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1.     CrossRef
• INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES
  Vanessa Gutierrez de ANDRADE, Fábio da Silva YAMASHIRO, Cássio Vieira OLIVEIRA, Alecsandro MOREIRA, Fernanda Cristina WINCKLER, Giovanni Faria SILVA
  Arquivos de Gastroenterologia.2018; 55(3): 274.     CrossRef
• Expert Opinion on Managing Chronic HCV Infection in Patients with Type 2 Diabetes Mellitus
  Luigi Elio Adinolf, Ira Jacobson, Mark Bondin, Patrice Cacoub
  Antiviral Therapy.2018; 23(1_suppl): 11.     CrossRef